Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers-Reference-Cited by-同舟云学术

Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

Published:2013-06-18 Issue:7 Volume:18 Page:516-524
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Ivory Sara E¹,Packham David K²,Reutens Anne T,Wolfe Rory¹,Rohde Richard D³,Lewis Julia⁴,Atkins Robert C¹,

Affiliation:

1. Department of Epidemiology and Preventive Medicine; Monash University; Melbourne; Victoria; Australia

2. Melbourne Renal Group; Nephrology Department; Royal Melbourne Hospital and Austin Hospital; Melbourne; Victoria; Australia

3. Collaborative Study Group; Chicago; Illinois; USA

4. Vanderbilt University Medical Centre; Nephrology; Nashville; Tennessee; USA

Publisher

Wiley

Subject

Nephrology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/nep.12053/fullpdf

Reference29 articles.

1. Diabetes: Diabetic kidney disease: Act now or pay later;Atkins;Nat. Rev. Nephrol.,2010

2. Proteinuria in diabetic kidney disease: A mechanistic viewpoint;Jefferson;Kidney Int.,2008

3. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes;Ninomiya;J. Am. Soc. Nephrol.,2009

4. Initiation and progression of diabetic nephropathy;Parving;N. Engl. J. Med.,1996

5. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes;Lewis;N. Engl. J. Med.,2001

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial;Kidney International Reports;2024-08

2. Proteinuria;Urinalysis in the Dog and Cat;2023-01-27

3. Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease;Expert Review of Clinical Pharmacology;2021-12-02

4. miRNA-483–5p Targets HDCA4 to Regulate Renal Tubular Damage in Diabetic Nephropathy;Hormone and Metabolic Research;2021-06-14

5. Association of platelet-to-lymphocyte ratio with kidney clinicopathologic features and renal outcomes in patients with diabetic kidney disease;International Immunopharmacology;2021-04